|
Papillary thyroid carcinoma
|
0.340 |
Biomarker
|
disease |
BEFREE |
Long noncoding RNA papillary thyroid carcinoma susceptibility candidate 3 (PTCSC3) is a novel lncRNA that was primarily detected in papillary thyroid carcinoma.
|
28187755 |
2017 |
|
Papillary thyroid carcinoma
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
MBIP and PTCSC3 displayed lower expression in PTC tissue in males than in females (p = 0.025 and p = 0.036, respectively).
|
27342578 |
2016 |
|
Papillary thyroid carcinoma
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
Expression data from PTC cell lines pinpointed S100A4 as the most significantly downregulated gene in the presence of PTCSC3.
|
26274343 |
2015 |
|
Papillary thyroid carcinoma
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
Our data suggest that SNP rs944289 predisposes to PTC through a previously uncharacterized, long intergenic noncoding RNA gene (PTCSC3) that has the characteristics of a tumor suppressor.
|
22586128 |
2012 |
|
Papillary thyroid carcinoma
|
0.340 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Our data suggest that SNP rs944289 predisposes to PTC through a previously uncharacterized, long intergenic noncoding RNA gene (PTCSC3) that has the characteristics of a tumor suppressor.
|
22586128 |
2012 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
LncRNA PTCSC3 is a known tumor suppressor, while its roles in other human diseases are unclear.
|
31196168 |
2019 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Long noncoding RNA (lncRNA) PTCSC3 (hereafter PTCSC3 is used to represent lncRNA PTCSC3) inhibits glioma and thyroid cancer, indicating its potential tumor suppression function in other types of cancers.
|
31026090 |
2019 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
PTCSC3 and Linc-pint overexpression inhibited tumor growth and cancer cell stemness, while Linc-pint knockdown played an opposite role an attenuated the effects of PTCSC3 overexpression.
|
31849528 |
2019 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
LncRNA PTCSC3 is a tumor suppressor in thyroid cancer, and its role in drug resistance of anaplastic thyroid cancer (ATC) to chemotherapy drug doxorubicin was investigated in this study.
|
29561707 |
2018 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
In vivo experiments verified the fact that overexpressed PTCSC3 inhibited tumor growth.
|
28513866 |
2017 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
S100A4 was upregulated in tumor tissue (P = 9.33 × 10(-7)) while PTCSC3 was strongly downregulated (P = 2.2 × 10(-16)).
|
26274343 |
2015 |
|
Neoplasms
|
0.070 |
GeneticVariation
|
group |
BEFREE |
Our data suggest that SNP rs944289 predisposes to PTC through a previously uncharacterized, long intergenic noncoding RNA gene (PTCSC3) that has the characteristics of a tumor suppressor.
|
22586128 |
2012 |
|
Thyroid carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
It is known that lncRNA PTCSC3 inhibits thyroid cancer and glioma and STAT3 promotes cancer development.
|
31171714 |
2019 |
|
Thyroid carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Long noncoding RNA (lncRNA) PTCSC3 (hereafter PTCSC3 is used to represent lncRNA PTCSC3) inhibits glioma and thyroid cancer, indicating its potential tumor suppression function in other types of cancers.
|
31026090 |
2019 |
|
Thyroid carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
LncRNA PTCSC3 is a tumor suppressor in thyroid cancer, and its role in drug resistance of anaplastic thyroid cancer (ATC) to chemotherapy drug doxorubicin was investigated in this study.
|
29561707 |
2018 |
|
Thyroid carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Previous studies have shown that PTCSC3 (Thyroid Carcinoma Susceptibility Candidate 3), miR-574-5p and Wnt/β-catenin were involved in PTC, but the potential pathogenic mechanism among them was still unclear.
|
28513866 |
2017 |
|
Thyroid carcinoma
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
Association of rs944289, which was previously known to confer risk for thyroid cancer, with FA, and the correlation between PTCSC3 and NRG1 expression demonstrates that predisposing genetic factors are partly common for benign and malignant thyroid tumors, and imply broader roles of the pathways they underlie in thyroid tumorigenesis, not limited to carcinogenesis.
|
25562676 |
2015 |
|
Malignant neoplasm of thyroid
|
0.040 |
Biomarker
|
disease |
BEFREE |
Long noncoding RNA (lncRNA) PTCSC3 (hereafter PTCSC3 is used to represent lncRNA PTCSC3) inhibits glioma and thyroid cancer, indicating its potential tumor suppression function in other types of cancers.
|
31026090 |
2019 |
|
Malignant neoplasm of thyroid
|
0.040 |
Biomarker
|
disease |
BEFREE |
It is known that lncRNA PTCSC3 inhibits thyroid cancer and glioma and STAT3 promotes cancer development.
|
31171714 |
2019 |
|
Thyroid Neoplasm
|
0.040 |
Biomarker
|
disease |
BEFREE |
Long noncoding RNA (lncRNA) PTCSC3 (hereafter PTCSC3 is used to represent lncRNA PTCSC3) inhibits glioma and thyroid cancer, indicating its potential tumor suppression function in other types of cancers.
|
31026090 |
2019 |
|
Thyroid Neoplasm
|
0.040 |
Biomarker
|
disease |
BEFREE |
It is known that lncRNA PTCSC3 inhibits thyroid cancer and glioma and STAT3 promotes cancer development.
|
31171714 |
2019 |
|
Tumor Cell Invasion
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
However, cell invasion and migration were not significantly affected by PTCSC3 overexpression.
|
31171714 |
2019 |
|
Tumor Cell Invasion
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
Ectopic expression of PTCSC3 decreased cell proliferation and invasion.
|
31814920 |
2019 |
|
Tumor Cell Invasion
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
Cancer cell migration and invasion were not significantly affected by PTCSC3 overexpression.
|
31026090 |
2019 |
|
Malignant neoplasm of thyroid
|
0.040 |
Biomarker
|
disease |
BEFREE |
LncRNA PTCSC3 is a tumor suppressor in thyroid cancer, and its role in drug resistance of anaplastic thyroid cancer (ATC) to chemotherapy drug doxorubicin was investigated in this study.
|
29561707 |
2018 |